ES2155802B1 - Procedimiento para reforzar y evaluar la eficacia de la actiovidad antitumoral de farmacos en bruto. - Google Patents

Procedimiento para reforzar y evaluar la eficacia de la actiovidad antitumoral de farmacos en bruto.

Info

Publication number
ES2155802B1
ES2155802B1 ES009902062A ES9902062A ES2155802B1 ES 2155802 B1 ES2155802 B1 ES 2155802B1 ES 009902062 A ES009902062 A ES 009902062A ES 9902062 A ES9902062 A ES 9902062A ES 2155802 B1 ES2155802 B1 ES 2155802B1
Authority
ES
Spain
Prior art keywords
procedure
antitumor
reinforcing
actiovity
pharmacos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES009902062A
Other languages
English (en)
Spanish (es)
Other versions
ES2155802A1 (es
Inventor
Kozo Niwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2155802A1 publication Critical patent/ES2155802A1/es
Application granted granted Critical
Publication of ES2155802B1 publication Critical patent/ES2155802B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
ES009902062A 1998-09-17 1999-09-16 Procedimiento para reforzar y evaluar la eficacia de la actiovidad antitumoral de farmacos en bruto. Expired - Lifetime ES2155802B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26375398 1998-09-17
JP10323374A JP2000159682A (ja) 1998-09-17 1998-11-13 生薬の抗腫瘍活性強化方法、抗腫瘍活性強化生薬含有組成物、生薬処理の抗腫瘍有効性評価方法、および生薬の抗腫瘍有効性評価方法

Publications (2)

Publication Number Publication Date
ES2155802A1 ES2155802A1 (es) 2001-05-16
ES2155802B1 true ES2155802B1 (es) 2001-12-01

Family

ID=26546176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009902062A Expired - Lifetime ES2155802B1 (es) 1998-09-17 1999-09-16 Procedimiento para reforzar y evaluar la eficacia de la actiovidad antitumoral de farmacos en bruto.

Country Status (19)

Country Link
JP (1) JP2000159682A (nl)
KR (1) KR20000023206A (nl)
CN (1) CN1255376A (nl)
AU (1) AU4486299A (nl)
BE (1) BE1012725A5 (nl)
CA (1) CA2282234A1 (nl)
DE (1) DE19944695A1 (nl)
DK (1) DK199901235A (nl)
ES (1) ES2155802B1 (nl)
FR (2) FR2783426A1 (nl)
GB (2) GB9920710D0 (nl)
ID (1) ID23150A (nl)
IL (1) IL131722A0 (nl)
IS (1) IS5183A (nl)
IT (1) IT1307267B1 (nl)
NL (2) NL1013049C2 (nl)
NO (1) NO994463L (nl)
SE (2) SE9903307L (nl)
SG (1) SG76631A1 (nl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354355T1 (de) * 2001-04-27 2007-03-15 Ajinomoto Kk Eine dispersion aus beta-glukan enthaltenden hochfeinen partikel, ein entsprechender herstellungsprozess und die verwendung der dispersion
CN1320121C (zh) * 2001-05-07 2007-06-06 拜奥哈步株式会社 制备蘑菇乳酸发酵溶液的方法及由此制备的蘑菇乳酸发酵溶液
JP4499979B2 (ja) * 2001-05-21 2010-07-14 コンビ株式会社 病原菌感染抑制用組成物
JP4561098B2 (ja) * 2001-06-01 2010-10-13 味の素株式会社 糖尿病用薬剤
JP4681801B2 (ja) * 2002-05-15 2011-05-11 ビーエイチエヌ株式会社 血管新生阻害剤およびその製造方法
KR100971599B1 (ko) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 혈관 관련 질환의 예방 또는 치료를 위한 조성물
JP4826696B2 (ja) * 2003-04-07 2011-11-30 ビーエイチエヌ株式会社 血管新生阻害剤
JP2005089417A (ja) * 2003-09-19 2005-04-07 Noevir Co Ltd 糖尿病予防・治療用組成物
JP4587441B2 (ja) * 2004-02-12 2010-11-24 株式会社クレハ 新規な糖尿病治療剤および食品
JP5034071B2 (ja) * 2004-09-17 2012-09-26 株式会社Ｓ・Ｓ・Ｉ 乳癌を抑制するカワリハラタケ抽出物
JP2006273835A (ja) * 2005-03-04 2006-10-12 Michishi Tani 悪性腫瘍治療剤及びそれを含む飲食品
US20120128856A1 (en) * 2009-07-31 2012-05-24 Ming East-West, Llc Maitake mushroom coffee
WO2011081024A1 (ja) * 2009-12-29 2011-07-07 株式会社富士見養蜂園 旨味食品及びその製造方法
CN106333969A (zh) * 2016-08-30 2017-01-18 青海民族大学 圆孢蘑菇抑制hdac1酶有效部位及制法和应用
CN106309511A (zh) * 2016-08-30 2017-01-11 青海民族大学 圆孢蘑菇抑制cdc25酶有效部位及制法和应用
WO2019104579A1 (en) * 2017-11-30 2019-06-06 SHIEH, Darbin Method for predicting and modulating susceptibility of cancer cell to programmed cell death
KR102646421B1 (ko) * 2020-12-16 2024-03-12 대한민국 잎새버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102602787B1 (ko) * 2020-12-16 2023-11-17 대한민국 꽃송이버섯 생리활성성분 및 영양성분의 함량을 증가시키는 방법
KR102584680B1 (ko) * 2020-12-17 2023-10-06 대한민국 생리활성 및 영양성분이 증가된 표고버섯차 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276413A (en) * 1975-12-18 1977-06-27 Kureha Chem Ind Co Ltd Production of oncostatic substances
US4177108A (en) * 1977-03-02 1979-12-04 Tetsuro Ikekawa Process for producing emitanin
DE2842691A1 (de) * 1978-09-30 1980-04-10 Karl Dr Med Theurer Energetische anregung biologischer arzneimittel
JPS57206618A (en) * 1981-06-12 1982-12-18 Noda Shiyokukin Kogyo Kk Preparation of antitumor substance
JPH02203765A (ja) * 1989-02-02 1990-08-13 Nippon Beet Sugar Mfg Co Ltd 抗腫瘍機能を有する食品及びその製造法
JP3357383B2 (ja) * 1991-08-14 2002-12-16 昌宏 黒田 低分子化植物性組成物
JP2955126B2 (ja) * 1992-06-22 1999-10-04 笑代 丹羽 医薬用油性製剤、食品用油性製剤およびそれらの製造方法
US6015913A (en) * 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans

Also Published As

Publication number Publication date
NL1013049A1 (nl) 2000-03-21
NO994463D0 (no) 1999-09-15
KR20000023206A (ko) 2000-04-25
NL1013049C2 (nl) 2002-01-11
SG76631A1 (en) 2000-11-21
FR2783426A1 (fr) 2000-03-24
ES2155802A1 (es) 2001-05-16
ITTO990784A1 (it) 2001-03-14
DE19944695A1 (de) 2000-03-30
IL131722A0 (en) 2001-03-19
BE1012725A5 (fr) 2001-02-06
CA2282234A1 (en) 2000-03-17
GB2341800A (en) 2000-03-29
SE0100195D0 (sv) 2001-01-24
GB9920710D0 (en) 1999-11-03
SE0100195L (sv) 2001-01-24
CN1255376A (zh) 2000-06-07
JP2000159682A (ja) 2000-06-13
NO994463L (no) 2000-03-20
NL1019705A1 (nl) 2002-01-29
IT1307267B1 (it) 2001-10-30
DK199901235A (da) 2000-03-18
IS5183A (is) 2000-03-17
AU4486299A (en) 2000-03-30
ITTO990784A0 (it) 1999-09-14
NL1019705C2 (nl) 2002-03-26
ID23150A (id) 2000-03-23
FR2788697A1 (fr) 2000-07-28
SE9903307D0 (sv) 1999-09-16
SE9903307L (sv) 2000-03-18
GB9921387D0 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
ES2155802B1 (es) Procedimiento para reforzar y evaluar la eficacia de la actiovidad antitumoral de farmacos en bruto.
Calzavara-Pinton et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
GR3034162T3 (en) Liposome-encapsulated taxol, its preparation and its use
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
ES2168395T3 (es) Nueva formulacion antitrombotica, procedimiento para su preparacion y utilizacion de la misma.
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
TR199701584T1 (xx) Anestezi etkili yeni farmas�tik kompozisyon
HUP0000057A2 (hu) Fotokemoterápiás készítmények
BR0113085A (pt) Composições que incluem bactérias que oxidam amÈnia para aumentar a produção de óxido nìtrico e precursores de óxido nìtrico, e métodos de uso dessas composições
ATE312635T1 (de) Ventilanordnung
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
FR2765483B1 (fr) Medicament destine a traiter les dysfonctions erectiles
ATE237331T1 (de) Deuterierte wirkstoffe in transdermaler applikation
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa
PT1313500E (pt) Associacoes de dalfopristina/quinupristina com o cefpirome
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010516

Kind code of ref document: A1

Effective date: 20010516